全文获取类型
收费全文 | 310007篇 |
免费 | 42055篇 |
国内免费 | 3649篇 |
专业分类
耳鼻咽喉 | 7272篇 |
儿科学 | 8327篇 |
妇产科学 | 6129篇 |
基础医学 | 27730篇 |
口腔科学 | 4869篇 |
临床医学 | 41380篇 |
内科学 | 77445篇 |
皮肤病学 | 11646篇 |
神经病学 | 26749篇 |
特种医学 | 14627篇 |
外科学 | 62007篇 |
综合类 | 2404篇 |
现状与发展 | 77篇 |
一般理论 | 81篇 |
预防医学 | 16634篇 |
眼科学 | 7660篇 |
药学 | 14952篇 |
中国医学 | 1650篇 |
肿瘤学 | 24072篇 |
出版年
2024年 | 748篇 |
2023年 | 5622篇 |
2022年 | 3947篇 |
2021年 | 7933篇 |
2020年 | 8273篇 |
2019年 | 5755篇 |
2018年 | 11626篇 |
2017年 | 10382篇 |
2016年 | 12354篇 |
2015年 | 13945篇 |
2014年 | 22132篇 |
2013年 | 23740篇 |
2012年 | 18331篇 |
2011年 | 17966篇 |
2010年 | 17483篇 |
2009年 | 20087篇 |
2008年 | 15105篇 |
2007年 | 13238篇 |
2006年 | 14852篇 |
2005年 | 11777篇 |
2004年 | 10154篇 |
2003年 | 8207篇 |
2002年 | 7450篇 |
2001年 | 8106篇 |
2000年 | 7002篇 |
1999年 | 6418篇 |
1998年 | 4896篇 |
1997年 | 4408篇 |
1996年 | 4271篇 |
1995年 | 4028篇 |
1994年 | 2670篇 |
1993年 | 2197篇 |
1992年 | 2928篇 |
1991年 | 2971篇 |
1990年 | 2394篇 |
1989年 | 2403篇 |
1988年 | 2157篇 |
1987年 | 1874篇 |
1986年 | 1887篇 |
1985年 | 1595篇 |
1984年 | 1188篇 |
1983年 | 1081篇 |
1982年 | 906篇 |
1981年 | 779篇 |
1980年 | 697篇 |
1979年 | 827篇 |
1978年 | 730篇 |
1977年 | 783篇 |
1974年 | 579篇 |
1972年 | 614篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Noninvasive imaging of cardiac fibrosis is important for early diagnosis and intervention in chronic heart diseases. Here, we investigated whether noninvasive, contrast agent-free MRI T2-mapping can quantify myocardial fibrosis in preclinical models of aging and pressure overload. Myocardial fibrosis and remodeling were analyzed in two animal models: (i) aging (15-month-old male CF-1 mice vs. young 6- to 8-week-old mice), and (ii) pressure overload (PO; by transverse aortic constriction in 4- to 5-month-old male C57BL/6 mice vs. sham-operated for 14 days). In vivo T2-mapping was performed by acquiring data during the isovolumic and early diastolic phases, with a modified respiratory and ECG-triggered multiecho TurboRARE sequence on a 7-T MRI. Cine MRI provided cardiac morphology and function. A quantitative segmentation method was developed to analyze the in vivo T2-maps of hearts at midventricle, apex, and basal regions. The cardiac fibrosis area was analyzed ex vivo by picro sirius red (PSR) staining. Both aged and pressure-overloaded hearts developed significant myocardial contractile dysfunction, cardiac hypertrophy, and interstitial fibrosis. The aged mice had two phenotypes, fibrotic and mild-fibrotic. Notably, the aged fibrotic subgroup and the PO mice showed a marked decrease in T2 relaxation times (25.3 ± 0.6 in aged vs. 29.9 ± 0.7 ms in young mice, p = 0.002; and 24.3 ± 1.7 in PO vs. 28.7 ± 0.7 ms in shams, p = 0.05). However, no significant difference in T2 was detected between the aged mild-fibrotic subgroup and the young mice. Accordingly, an inverse correlation between myocardial fibrosis percentage (FP) and T2 relaxation time was derived (R2 = 0.98): T2 (ms) = 30.45 – 1.05 × FP. Thus, these results demonstrate a statistical agreement between T2-map–quantified fibrosis and PSR staining in two different clinically relevant animal models. In conclusion, T2-mapping MRI is a promising noninvasive contrast agent-free quantitative technique to characterize myocardial fibrosis. 相似文献
12.
13.
14.
15.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
16.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
17.
18.
19.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
20.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献